NCT04724421

Brief Summary

The objective of this Expanded Access Protocol (EAP) is to provide voxelotor for the treatment of sickle cell disease (SCD): The study GBT440-041 is the EAP for pediatric patients aged 6 months to 11 years who have no alternative treatment options and are ineligible to participate in a clinical trial of voxelotor and the study C5341057 is the EAP for adults/adolescents 12 years of age and older for patients who cannot satisfactorily be treated with an authorized medicinal product

Trial Health

60
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Geographic Reach
2 countries

37 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 21, 2021

Completed
5 days until next milestone

First Posted

Study publicly available on registry

January 26, 2021

Completed
Last Updated

November 20, 2024

Status Verified

November 1, 2024

First QC Date

January 21, 2021

Last Update Submit

November 15, 2024

Conditions

Keywords

Voxelotor

Interventions

tablet or powder for oral suspension

Also known as: GBT440

Eligibility Criteria

Age6 Months - 11 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Documented diagnosis of sickle cell disease of any genotype
  • Ineligible or unable to participate in actively recruiting clinical studies of voxelotor
  • Baseline hemoglobin (Hb) ≤10.5 g/dL
  • No alternative treatment options in the judgement of the treating Investigator
  • Participants who, if female of childbearing potential (post-menarche), and are sexually active, agree to use highly effective methods of contraception from study start to 30 days after the last dose of voxelotor
  • Written informed parental/guardian consent and participant assent (if applicable) has been obtained per Institutional Review Board (IRB) policy and requirements, consistent with International Council for Harmonisation (ICH) guidelines

You may not qualify if:

  • Receiving chronic red blood cell (RBC) transfusion therapy for primary or secondary stroke prevention
  • Hepatic dysfunction characterized by alanine aminotransferase (ALT) \>4 × the upper limit of normal (ULN) for age
  • Severe renal dysfunction (estimated glomerular filtration rate \[eGFR\] \<30 mL/min/1.73 m2 by Schwartz formula)
  • Clinically significant bacterial, fungal, parasitic, or viral infection that requires therapy:
  • Patients with acute bacterial infection requiring antibiotic use should delay screening/enrollment until the course of antibiotic therapy has been completed.
  • Patients with known active hepatitis A, B, or C or who are known to be Human Immunodeficiency Virus (HIV) positive
  • Any condition affecting drug absorption, such as major surgery involving the stomach or small intestine (prior cholecystectomy is acceptable)
  • Female who is pregnant or breastfeeding
  • Participated in another clinical trial of an investigational drug or medical device, within 30 days or 5 half-lives of the investigational drug (whichever is longer) prior to informed consent for the EAP, or is currently participating in another trial of an investigational drug or medical device
  • Medical, psychological, or behavioral conditions, that, in the opinion of the Investigator, may preclude informed consent, safe participation, or compliance with the protocol procedures
  • Use of herbal medications (eg, St. John's wort), sensitive cytochrome P450 (CYP) 3A4 substrates with a narrow therapeutic index, or strong CYP3A4 inducers
  • Active symptomatic COVID-19 infection
  • Documented diagnosis of SCD of any genotype confirmed by laboratory genetic testing
  • Aged 12 years and older
  • Haemoglobin ≥5.5 and ≤ 10.5 g/dL, based on a test performed according to local standard of care
  • +7 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (37)

Phoenix Children's Hospital

Phoenix, Arizona, 85016, United States

Location

Rady Children's Hospital San Diego

San Diego, California, 92123, United States

Location

Nemours/Alfred I. duPont Hospital for Children

Wilmington, Delaware, 19803, United States

Location

Children's National Hospital / Children's National Health System

Washington D.C., District of Columbia, 20010, United States

Location

Children's National Medical Center

Washington D.C., District of Columbia, 20010, United States

Location

Baptist Medical Center/Wolfson Children's Hospital

Jacksonville, Florida, 32207, United States

Location

Nemours Children's Health, Jacksonville

Jacksonville, Florida, 32207, United States

Location

Nemours Children's Hospital

Orlando, Florida, 32827, United States

Location

Children's Healthcare of Atlanta Scottish Rite

Atlanta, Georgia, 30342, United States

Location

AU Medical Center Clinical Research Pharmacy

Augusta, Georgia, 30912, United States

Location

Augusta University

Augusta, Georgia, 30912, United States

Location

Children's Hospital of Georgia

Augusta, Georgia, 30912, United States

Location

Memorial Health University Medical Center

Savannah, Georgia, 31404, United States

Location

Tulane Lakeside

Metairie, Louisiana, 70001, United States

Location

Tulane University Hospitals and Clinics

New Orleans, Louisiana, 70112, United States

Location

Children's Hospital

New Orleans, Louisiana, 70118, United States

Location

Childrens Hospital of NOLA

New Orleans, Louisiana, 70118, United States

Location

University Of Michigan Hospitals

Ann Arbor, Michigan, 48109, United States

Location

Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, 08901, United States

Location

Newark Beth Israel Medical Center & Children's Hospital of New Jersey

Newark, New Jersey, 07112, United States

Location

BronxCare Health System

The Bronx, New York, 10457, United States

Location

Jacobi Medical Center

The Bronx, New York, 10461, United States

Location

East Carolina University Brody School of Medicine(ECU)

Greenville, North Carolina, 27834, United States

Location

ECU Physicians, Brody Outpatient Clinic

Greenville, North Carolina, 27834, United States

Location

University Hospitals Cleveland Medical Center

Cleveland, Ohio, 44106, United States

Location

Medical University of South Carolina: Investigational Drug Services Pharmacy

Charleston, South Carolina, 29425, United States

Location

Medical University of South Carolina: Shawn Jenkins Women's and Children's Hospital

Charleston, South Carolina, 29425, United States

Location

Medical University of South Carolina

Charleston, South Carolina, 29425, United States

Location

Prisma Health - Upstate

Greenville, South Carolina, 29605, United States

Location

St. Jude Children's Research Hospital

Memphis, Tennessee, 38105, United States

Location

Cook Children's Health Care System

Fort Worth, Texas, 76104, United States

Location

Pediatric Specialists of Virginia (Inova Ashburn HealthPlex)

Ashburn, Virginia, 20148, United States

Location

Pediatric Specialists of Virginia (Schar Cancer Institute)

Fairfax, Virginia, 22031, United States

Location

Multihemo Serviços Médicos S/A

Recife, Pernambuco, 50070-460, Brazil

Location

Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto - USP

Ribeirão Preto, São Paulo, 14048-900, Brazil

Location

HEMORIO - Hematologia Laboratorial

Rio de Janeiro, 20211-030, Brazil

Location

ESHO Empresa de Serviços Hospitalares S.A/ Hospital Samaritano de Higienópolis

São Paulo, 01232-010, Brazil

Location

Related Links

MeSH Terms

Conditions

Anemia, Sickle Cell

Interventions

voxelotor

Condition Hierarchy (Ancestors)

Anemia, Hemolytic, CongenitalAnemia, HemolyticAnemiaHematologic DiseasesHemic and Lymphatic DiseasesHemoglobinopathiesGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and Abnormalities

Study Officials

  • Pfizer CT.gov Call Center

    Pfizer

    STUDY DIRECTOR

Study Design

Study Type
expanded access
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 21, 2021

First Posted

January 26, 2021

Last Updated

November 20, 2024

Record last verified: 2024-11

Locations